Meridian Wealth Management LLC Acquires New Holdings in TransMedics Group, Inc. $TMDX

Meridian Wealth Management LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the second quarter, HoldingsChannel.com reports. The fund bought 1,502 shares of the company’s stock, valued at approximately $201,000.

A number of other hedge funds have also added to or reduced their stakes in TMDX. CWM LLC lifted its holdings in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company’s stock valued at $62,000 after buying an additional 155 shares during the period. Victory Capital Management Inc. increased its position in TransMedics Group by 3.8% during the first quarter. Victory Capital Management Inc. now owns 8,365 shares of the company’s stock valued at $563,000 after acquiring an additional 308 shares during the last quarter. Jennison Associates LLC lifted its holdings in TransMedics Group by 3.6% in the first quarter. Jennison Associates LLC now owns 9,217 shares of the company’s stock valued at $620,000 after acquiring an additional 316 shares during the period. Lindbrook Capital LLC lifted its holdings in TransMedics Group by 69.3% in the first quarter. Lindbrook Capital LLC now owns 2,742 shares of the company’s stock valued at $184,000 after acquiring an additional 1,122 shares during the period. Finally, Allianz Asset Management GmbH purchased a new position in TransMedics Group in the first quarter worth about $343,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director owned 2,866 shares in the company, valued at approximately $373,869.70. This represents a 59.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 7.00% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Piper Sandler reduced their price target on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a research report on Thursday, October 30th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective for the company. Finally, Canaccord Genuity Group upped their price objective on TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Price Performance

NASDAQ TMDX opened at $117.07 on Wednesday. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $145.50. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 47.40 and a beta of 2.05. The company’s 50 day moving average is $119.16 and its two-hundred day moving average is $120.33.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.